Experts say 2026 could be a crucial year for drug patents, with the likely emergence of fresh disputes over follow-on patents
Popular Posts
-
With the right scrutiny and security guardrails, underlying competitive advantage awaits capture
-
Raajmarg Infra Investment Trust IPO | The infrastructure investment trust approached capital markets to raise Rs 6,000 crore via initial pu...
